Introduction
Graves' orbitopathy (GO) is a condition frequently associated with Graves' disease (GD) (autoimmune thyroid disease, goiter and thyrotoxicosis). It can be clinically relevant in almost 70% of patients but with sensitive imaging techniques it can be demonstrated in over 90% of patients with GD [1] . Th e most common symptoms include lid retraction (almost invariably the upper lid being aff ected) [2] , periorbital swelling and redness, conjunctival redness, lagophtalmos and proptosis [3] . Th e change in appearance can be very disturbing for patient but the true danger is represented by the most severe complications -corneal ulcerations and optic nerve ischemia leading in severe cases to sight loss [4] .
Th e onset of GO varies in association with thyroid disease, it may be present from the beginning of hyperthyroidism, it can follow within months after the thyroid dysfunction, or, in some cases it can precede the thyrotoxicosis. A small percentage of GO patients develop GO without any evidence of thyroid disease, called euthyroid GO [5, 6] . Clinical evaluation of GO is made upon signs and symptoms according to algorithms off ered by the European Group on Graves' Orbitopathy (EUGOGO) [7, 8, 9, 10] . Th is includes appreciation of severity by the NOSPECS stages and activity by the Clinical Activity Score (CAS) ( Tables I and II) .
Th e pathogenesis of GO is based upon the concept of the common antigen shared by the thyroid and orbit as well, presumably the thyroid stimulating hormone (TSH) receptor. Stimulating antibodies attached to the receptor generate a cascade of immune reactions and cytokine production leading to adipogenesis and expansion of the adipose tissue within the connective sheets in the orbit, infl ammatory infi ltration and production of glycosaminoglycans [11, 12] .
Th e recruited infl ammatory cells, T and B lymphocytes, macrophages, mast cells, orbital fi broblasts interact and promote local infl ammation by signal molecules represented by cytokines: IL-1 (interleukin-1), IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, IL-18, IFN- (interferon gamma), TNF- (tumor necrosis factor alpha), TGF- (transforming growth factor beta), RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) and MCP-1 (monocyte chemoattractact protein). In recent-onset GO Th 1 pattern dominates (IL-2, IFN-, TNF-), and in remitted, inactive disease the Th 2 pattern cytokines (IL-4, IL-5, IL-10) represent the major cytokines [13, 14] . Th e result of cytokine stimulation on the orbital fi broblast is the acceleration of acute immune reactions like expression of heat shock protein 72, production of prostaglandin E2, enhancement of glycosaminoglycan synthesis, adipocyte diff erentiation and adipogenesis [15, 16] .
Th e most important environmental factor in close association with the progression of GO is smoking. SmokCorrespondence to: Zsuzsánna Réti E-mail: dzso_aok@yahoo.com ing, even passive smoking, represents a risk factor for more severe orbital involvement and higher activity score by the interaction with proinfl ammatory cytokines [17, 18] .
Treatment of GO is focused mainly on equilibration of thyroid function and reduction of infl ammation by local and systemic anti-infl ammatory drugs according to guidelines set by EUGOGO [19] .
Subjects and methods
In this study participated 25 patients with Graves' disease and Graves' orbitopathy, followed-up in the Endocrinology Clinic of Tîrgu Mureș. We investigated serum levels of interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin 6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-) and interferon-gamma (IFN-), in order to examine the contribution of these cytokines in the immune response of the disease. Diagnosis of Graves disease was made upon clinical and biochemical-immunological criteria: goiter, signs of thyrotoxicosis (suppressed TSH with elevated FT4 and/or FT3) or treatment for the disease, antithyroid antibodies (TSH Receptor Antibodies-TRAb, antithyroid peroxidase-TPO), and ophthalmological exam for the presence of the orbitopathy.
Th e onset of Graves' disease and orbitopathy were noted, as the time elapsed between the thyroid symptoms and ophthalmic symptoms. Smoking status was recorded as smoker (even patients who quit in time) and non-smoker (never smoked).
Serum cytokines (IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IFN-, TNF-) were measured by biochip-cytokine array (Randox Laboratories Ltd., UK) with patients' informed consent at the same time with routine blood tests on admission.
Statistical analysis was performed using JMP 7.0 (descriptive statistics, t-test, Chi-test, Kruskall-Wallis test), p <0.05 was considered statistically signifi cant.
Results
Patient distribution: of the 25 patients 10 were male (40%), 15 female (60%), mean age 43.08 years (±2.16), the youngest patient was 24, the oldest 58. A number of 14 of patients were smokers (7 male and 7 female), 11 never smoked (3 male, 8 female).
Ophthalmopathy onset in relation to Graves' disease evolution: in 12 patients ophthalmological signs appeared simultaneously (within 1-2 months) with thyroid disease, in 13 (52%) patients there was a known history of thyroid disease, before the orbitopathy appeared. In these, 5 patients developed ophthalmic disease within 12 months, another 6 within 12 to 36 months, and 2 after 3 years after the beginning of hyperthyroidism (Figure 1 ). Staging the disease severity and activity according to guidelines of EUGOGO, available at http://eugogo.eu/ clinical_evaluation.php, our patients presented as follows: 17 patients were considered as having mild or moderate GO with NOSPECS < stage IIIb, of these 12 were stage II, and 5 patients had stage III ophthalmopathy; 8 patients had severe GO, defi ned as stages IIIc-V, only one patient having optic neuropathy, therefore recorded as stage V. Clinically active disease was considered when clinical activity score (CAS) exceeded 4 points, so 12 patients had inactive disease, and 13 patients had active GO ( six patients with CAS = 4, fi ve patients with CAS = 5, and two patients with CAS = 6).
Mean cytokine level measurements are listed in Table III . We wanted to see if there's a diff erence in serum cytokine levels in smokers vs. non-smokers. After statistical analysis we found that smokers have higher IL-6 levels (6.42 ± 1.98 pmol/l vs. 2.12 ± 1.75 pmol/l, p < 0.05), and lower MCP1 According to disease activity defi ned by CAS and cytokine profi le, we found that there is a weak positive correlation between IL-10 (r = 0.26, p < 0.05) and clinical activity score, IFN- and clinical activity score (r = 0.23, p < 0.05), and a weak negative correlation between IL-1 and CAS (r = -0.24, p < 0.05) (Figure 2 ). For the rest of the studied parameters, we found no statistical correlation regarding disease activity and serum cytokine levels.
Discussions
In the present study we demonstrated diff erences in serum interleukin levels in patients with Graves' orbitopathy. Several studies tried to defi ne the exact serum interleukin profi le in attempt to predict progression and response to medical treatment. Some of these cytokines are involved in Th 1 cell mediated immune reactions (IL-2, TNF- and IFN-), while others are related to Th 2 humoral responses (IL-4, IL-5, IL-10). Other cytokines are secreted by activated fibroblasts or macrophages (IL-1, IL-6, IL-8,IL-16, TGF-, RANTES, PGE2) and they sustain chronic infl ammation [8, 20] . IL-1, TNF- and IFN- are pro-infl ammatory cytokines that increase adhesion molecule (ICAM-1), heat shock protein 72, HLA class II molecules' expression on orbital fi broblasts and stimulate adipocyte diff erentiation. Th e stimulated fi broblasts secrete small cytokines as MCP-1 and IL-8, which participate in recruitment of monocytes, lymphocytes and neutrophils to the site of infl ammation. In addition, studies have shown that IL-1 is responsible for the production of glycosaminoglycans. Blocking TNF- or IL-1 production by specifi c monoclonal antibodies represents a promising therapeutic possibility for a subset of patients. Some studies show that there is an increased level of IL-10 in GO patients that respond to steroid treatment, and that the proportion of IL-10 vs. IL-4 (mainly an antiinfl ammatory cytokin) could be used for selecting patients before therapy. IL-6 has been shown to stimulate the expression of TSH-receptor gene and is a negative predictive factor for response to treatment [15, 16, 24] . Th ese results are controversial, mainly due to the small number of patients included in studies. In our study IL-6 levels proved to be more elevated in smoker patients when compared to non-smokers suggesting the proinfl ammatory potential of smoking on orbital fi broblasts by increasing HLA II molecule expression. Th is fi nding is important because smokers are at higher risk in developing GO, the response to medical treatment is poorer and progression is more severe in active smokers [18, 21, 22, 23] . Th erefore it is important for patients to understand that quitting can improve curing chances, and smoking being a modifi able risk factor they should be encouraged and helped to cease smoking.
Th e lower IL-8, MCP-1 and TNF- levels found in smokers suggest that the infl ammation is exacerbated in smokers and cytokines responsible for fi broblast activation and adipocyte diff erentiation could be slightly reduced. Considering that almost half of patients presented had recent-onset GO, we would have expected to have more evident Th 1 pattern in cytokine profi le, namely elevated IL-2, IFN- and TNF-, described in other studies [13, 14] . Th e small number of patients may be the cause of this bias.
Several studies suggested also that serum interleukin levels, and more evident retroorbital cytokine levels are strongly correlated with disease activity [20, 24, 25] . We found that only for IL-10 and IFN- there is a slight increase with clinical activity score, and that IL-1 levels decreased with higher scores of disease activity. Th e discrepancy of cytokine profi les may refl ect diff erent patient characteristics, such as disease stage and disease activity.
Conclusion
Our work shows that there is a diff erence in serum IL-6 in smoking and non-smoking GO patients. We recommend stopping smoking for all patients with Graves disease and/ or Graves orbitopathy.
Th e activity of the disease characterized by the extension of infl ammation and impairment of function correlated with increasing serum IL-10, IFN- and lower IL-1 levels. Th e importance of these fi ndings need to be assessed in larger patient populations.
As a conclusion, our study suggests that cytokines play a major role in sustaining and promoting infl ammation in the retro orbital tissue of GO patients, and serologic profi ling could help in choosing more aggressive treatment protocols in patients with active disease.
